Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
3
30%
Ph phase_2
6
60%
Ph phase_3
1
10%

Phase Distribution

3

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(2)
Other(2)

Detailed Status

Completed6
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)

Trials by Status

terminated110%
unknown220%
completed660%
withdrawn110%

Recent Activity

0 active trials
Showing 5 of 10
terminatedphase_2

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

NCT00997243
completedphase_1

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT00283114
unknownphase_2

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

NCT00006084
unknownphase_3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

NCT00006045
completedphase_2

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

NCT00002800
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00997243Phase 2

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Terminated
NCT00283114Phase 1

A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Completed
NCT00006084Phase 2

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

Unknown
NCT00006045Phase 3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Unknown
NCT00002800Phase 2

Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Completed
NCT00002890Phase 1

Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia

Completed
NCT00002609Phase 2

Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission

Completed
NCT00016159Phase 2

Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia

Completed
NCT00003984Phase 2

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Withdrawn
NCT00502112Phase 1

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Completed

All 10 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
10